popular wires

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of...

How we're positioning for three historic shifts of global market forces

And two small-cap companies with stellar earnings growth.

A nice bounce as investors factored out a range of outcomes worse than whatever's actually happened since Israel's missile strike on Iran.

Get up to date on overnight market activity and the big events for the day.

The market is looking supportive of valuations and Eiger Capital's Stephen Wood sees opportunities.

The co-founder of Oaktree Capital talks opportunity cost, the importance of risk to investing, and their similarities to a game of chess.

And where the big opportunities lie for investors beyond AI, according to Morgan Stanley Wealth Management's Alexandre Ventelon

Five research tips and five red flags when weighing opportunities, plus a stock whose earnings could rise 10% p.a. in the next few years.

Get up to date on overnight market activity and the big events for the day.

When a new product launches, sometimes it takes a while to gain some traction with only a minority tending to be the early adopters. For example, when the first home...

Recent advances in semiconductors and large language models (LLMs) are enhancing the accessibility, integration, and distribution of sophisticated AI systems. Early...

Where Cyan’s Dean Fergie sees opportunity in smaller Aussie companies, including one unloved name that could rise five-fold from here

The major brokers have reviewed Pilbara’s latest quarterly results, and despite many positive comments, the consensus is it's too expensive.

And other key take outs from our newly released Australian Equities Outlook.

The next instalment in this series of 'The $10,000 Idea' features a Livewire favourite.

Short sellers are searching for evidence the $1.2 billion company is just a house of cards, but Cettire's bulls remain undeterred.

Emanuel Datt explores an unloved biopharma company, a manganese miner and a rare earths explorer that grew into a $1bn market cap producer.

Is there more in the tank for gold prices? Lowell Resources’ John Forwood & Acorn Capital’s Rick Squire provide their take.

Central banks are starting to splinter, and that has big implications for whatever asset class you are in.